...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Question for the board!

Don is waiting for the BETonMACE to succeed and that will give Zenith's IPO the impetus it needs to come out of the gate in a big way. The market loves winners. When the market sees Don's success with RVX the market will believe that he can do it again with Zenith. That will give him all the money he needs to fund and grow the business to attract BP partnerships. May even go directly to a Nasdaq listing. (IMO)

 

Koo

Share
New Message
Please login to post a reply